Published in Trends Mol Med on May 01, 2001
Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet (2000) 4.74
A major quantitative-trait locus for mole density is linked to the familial melanoma gene CDKN2A: a maximum-likelihood combined linkage and association analysis in twins and their sibs. Am J Hum Genet (1999) 2.15
Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer (2005) 2.13
Cytoplasmic accumulation of cdc25B phosphatase in mitosis triggers centrosomal microtubule nucleation in HeLa cells. J Cell Sci (1996) 1.99
A Taq I polymorphism for the human transforming growth factor alpha gene (TGFA). Nucleic Acids Res (1987) 1.88
Genome scan of schizophrenia. Am J Psychiatry (1998) 1.74
Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ Res (2000) 1.72
MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet (2001) 1.67
Leptin and the risk of Barrett's oesophagus. Gut (2008) 1.54
The CDKN2A (p16) gene and human cancer. Mol Med (1997) 1.46
Gene expression of lung squamous cell carcinoma reflects mode of lymph node involvement. Eur Respir J (2007) 1.43
Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol (1996) 1.36
Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res (1997) 1.33
The contribution of the DFNB1 locus to neurosensory deafness in a Caucasian population. Am J Hum Genet (1995) 1.30
Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosomes Cancer (1996) 1.25
Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res (1994) 1.24
Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet (1995) 1.18
Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res (1996) 1.10
Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas. Melanoma Res (1995) 1.10
CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res (1997) 1.07
Separate and interacting effects within the catechol-O-methyltransferase (COMT) are associated with schizophrenia. Mol Psychiatry (2005) 1.04
Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J Natl Cancer Inst (2010) 1.04
Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. Cancer Res (2001) 1.03
Analysis of gene amplification in head-and-neck squamous-cell carcinoma. Int J Cancer (1991) 1.00
Second stage of a genome scan of schizophrenia: study of five positive regions in an expanded sample. Am J Med Genet (2000) 0.98
Germline CDKN2A mutations in childhood melanoma. J Natl Cancer Inst (1997) 0.98
Localization of multiple melanoma tumor-suppressor genes on chromosome 11 by use of homozygosity mapping-of-deletions analysis. Am J Hum Genet (2000) 0.97
Functional reassessment of P16 variants using a transfection-based assay. Int J Cancer (1999) 0.97
Hepatocellular carcinoma mutation. Nature (1991) 0.95
Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. Oncogene (1997) 0.94
A genetic model of melanoma tumorigenesis based on allelic losses. Genes Chromosomes Cancer (1995) 0.93
Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations. Hum Mutat (1998) 0.90
Exclusion of the familial melanoma locus (MLM) from the PND/D1S47 and MYCL1 regions of chromosome arm 1p in 7 Australian pedigrees. Genomics (1992) 0.90
Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines. Oncogene (1995) 0.89
Loss of p16 expression is associated with histological features of melanoma invasion. Melanoma Res (2002) 0.88
The phospholipase C beta 3 gene located in the MEN1 region shows loss of expression in endocrine tumours. Hum Mol Genet (1994) 0.88
PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines. Melanoma Res (2002) 0.87
p53 gene in hepatocellular carcinomas from Australia. Cancer Detect Prev (1994) 0.86
Multiple splicing variants of cdc25B regulate G2/M progression. Biochem Biophys Res Commun (1999) 0.86
Clonal loss of INT-2 alleles in sporadic and familial pancreatic endocrine tumours. Br J Cancer (1990) 0.86
CDKN2A is not the principal target of deletions on the short arm of chromosome 9 in neuroendocrine (Merkel cell) carcinoma of the skin. Int J Cancer (2001) 0.86
Loss of somatic heterozygosity in hepatocellular carcinoma. Cancer Res (1991) 0.86
Simple tandem repeat allelic deletions confirm the preferential loss of distal chromosome 6q in melanoma. Int J Cancer (1994) 0.86
CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. Int J Cancer (1997) 0.85
Linkage mapping of melanoma (MLM) using 172 microsatellite markers. Genomics (1992) 0.85
Evidence for microsatellite instability in bilateral breast carcinomas. Cancer Lett (2000) 0.85
Lack of augmentation of tumor spectrum or severity in dual heterozygous Men1 and Rb1 knockout mice. Oncogene (2006) 0.83
Single base mutation in the hormone binding domain of the thyroid hormone receptor beta gene in generalised thyroid hormone resistance demonstrated by single stranded conformation polymorphism analysis. Biochem Biophys Res Commun (1991) 0.83
Involvement of p16CDKN2A in cell cycle delays after low dose UV irradiation. Mutat Res (1998) 0.83
Molecular tools for presymptomatic testing in multiple endocrine neoplasia type 1. J Intern Med (1995) 0.82
Origin of rare Ha-ras alleles: relationship of VTR length to a 5' polymorphic Xho I site. Genet Res (1989) 0.81
Loss of alleles on the short arm of chromosome 11 in a hepatoblastoma from a child with Beckwith-Wiedemann syndrome. Hum Genet (1988) 0.81
Restoration of CDKN2A into melanoma cells induces morphologic changes and reduction in growth rate but not anchorage-independent growth reversal. J Invest Dermatol (1997) 0.80
Loss of heterozygosity studies in squamous cell carcinomas of the head and neck. Head Neck (1997) 0.80
Ocular melanoma is not associated with CDKN2A or MC1R variants--a population-based study. Melanoma Res (2003) 0.79
Mutation analysis of the CDKN2A promoter in Australian melanoma families. Genes Chromosomes Cancer (2001) 0.79
Linkage analysis in familial melanoma kindreds to markers on chromosome 6p. Int J Cancer (1994) 0.79
Effect of N-hydroxyparacetamol on cell cycle progression. Biochem Pharmacol (1986) 0.78
Prophylactic but not therapeutic activity of a monoclonal antibody that neutralizes the binding of VEGF-B to VEGFR-1 in a murine collagen-induced arthritis model. Rheumatology (Oxford) (2008) 0.78
Refined localization of the melanoma (MLM) gene on chromosome 9p by analysis of allelic deletions. Oncogene (1994) 0.77
UV induction of transforming growth factor alpha in melanoma cell lines is a posttranslational event. J Cell Physiol (1992) 0.77
Loss of allelic heterozygosity on distal chromosome 1p in Merkel cell carcinoma. A marker of neural crest origins? Cancer Genet Cytogenet (1991) 0.76
The MLLT3 gene maps between D9S156 and D9S171 and contains an unstable polymorphic trinucleotide repeat. Genomics (1994) 0.76
Lack of genetic and epigenetic changes in CDKN2A in melanocytic nevi. J Invest Dermatol (2001) 0.76
Genomic organization and complete cDNA sequence of the human phosphoinositide-specific phospholipase C beta 3 gene (PLCB3). Genomics (1995) 0.76
Genetic studies of thymic carcinoids in multiple endocrine neoplasia type 1. J Med Genet (1994) 0.75
Conditions for generating well-resolved human DNA fingerprints using M13 phage DNA. Nucleic Acids Res (1990) 0.75
Confirmation of susceptibility locus on chromosome 13 in Australian breast cancer families. Hum Genet (1996) 0.75
Rare c-Ha-ras-1 alleles in human leukaemia. Nucleic Acids Res (1989) 0.75
Spontaneous and 4-nitroquinoline 1-oxide-induced G2 chromosome aberrations in lymphoblasts from familial melanoma patients. Cancer Genet Cytogenet (1989) 0.75
p-Aminophenol induced DNA damage and cytotoxicity enhanced by autoxidation. Life Sci (1985) 0.75
No support for linkage to the bipolar regions on chromosomes 4p, 18p, or 18q in 43 schizophrenia pedigrees. Am J Med Genet (2000) 0.75
Haplotype analysis limits the position of the familial melanoma locus on 9p to the D9S169-D9S156 interval. Melanoma Res (1994) 0.75
Inhibition of DNA, RNA and protein synthesis and chromatin alteration by N-hydroxyphenacetin. Xenobiotica (1987) 0.75
Predictive diagnosis of multiple endocrine neoplasia (MEN 1) in four Australian kindreds. Aust N Z J Med (1996) 0.75
Inhibition of DNA synthesis and alteration to DNA structure by the phenacetin analog p-aminophenol. Biochem Pharmacol (1982) 0.75
Genetic mapping of the multiple endocrine neoplasia type 1 locus at 11q13. J Intern Med (1995) 0.75
Microsatellite instability in melanoma. Melanoma Res (1994) 0.75
G protein mutations in tumours of the pituitary, parathyroid and endocrine pancreas. Biochem Biophys Res Commun (1995) 0.75
Effect of N-hydroxyparacetamol on DNA, RNA, and protein synthesis and chromatin structure. Mol Pharmacol (1986) 0.75